Is mean platelet volume a marker of platelet reactivity and cardiovascular risk?

Mean platelet volume (MPV) is a well-established surrogate marker for platelet reactivity and a robust predictor of cardiovascular risk. Larger platelets, which yield a higher MPV, are typically younger (reticulated) and possess distinct physiological advantages that enhance their functional response during clot formation.

Mechanistic evidence for reactivity

The hyper-reactivity of high-MPV platelets is driven by several convergent molecular mechanisms:

• Enhanced Receptor Density: Larger platelets exhibit higher surface expression of critical receptors, including GPVI (collagen receptor) and α2A receptors, increasing their sensitivity to agonists like collagen and epinephrine.
• Superior Signaling and Degranulation: These cells demonstrate more robust calcium mobilization from intracellular stores and increased P-selectin (CD62P) surface exposure, indicating more efficient degranulation compared to smaller platelets.
• Transcriptional Capacity: High-MPV platelets contain higher RNA content and upregulated functional transcriptomes, allowing for increased protein synthesis and metabolic activity.

Clinical and thrombotic risk

Elevated MPV is directly associated with a pro-thrombotic state and serves as a biomarker for adverse clinical outcomes:

• MACE and Mortality: A meta-analysis of 10 prospective studies involving 11,647 patients found that elevated MPV is significantly associated with a 2.10 hazard ratio (HR) for short-term mortality and a 1.14 HR for long-term major adverse cardiovascular events (MACE).
• Acute Events: MPV levels frequently rise during the first 12 hours of a myocardial infarction. Both admission MPV and the rate of change in MPV (ΔMPV) independently predict 12-month MACE rates and mortality.
• Inflammatory Integration: Beyond acute thrombosis, large platelets contribute to the progression of atherosclerosis by mediating inflammatory pathways, further elevating long-term cardiovascular risk.

Considerations

While the mechanistic link is strong, the correlation between MPV and specific ex vivo aggregation tests (like ADP-induced aggregation) can be inconsistent in healthy populations. Additionally, in certain acute settings like deep vein thrombosis, MPV may occasionally appear lower due to the consumption of these larger, more active platelets during the thrombotic process.

Bottom line

Elevated mean platelet volume is a scientifically supported marker of increased platelet reactivity and is significantly associated with higher risks of thrombosis and major adverse cardiovascular events. For a 48-year-old male, MPV provides valuable prognostic information regarding underlying pro-thrombotic activity.